Takeda
says cancer drug Alunbrig shows longer benefit vs. crizotinib
Send a link to a friend
[November 25, 2019]
By Rocky Swift
(Reuters) - Japan's biggest drugmaker,
Takeda Pharmaceutical Co Ltd, said long-term data show better outcomes
for its Alunbrig drug in certain lung cancer patients compared to an
existing treatment.
|
Oncology is a pillar for Takeda as it refocuses on core businesses
following last year's $59 billion takeover of Britain's Shire. The
announcement followed a week of investor conferences at home and in
the United States intended to show that its drug pipeline is robust
enough to fuel continued growth.
Alunbrig, Takeda's trade name of brigatinib, reduced the risk of
disease progression by 76% in patients whose cancer had spread to
the brain and by 57% in all patients when compared to crizotinib.
The results were released today at the European Society for Medical
Oncology Asia Congress in Singapore.
"This is a profoundly exciting study," said Rachael Brake, Takeda's
global program leader in oncology. "The benefit in the overall study
population, as well as in patients with baseline brain metastises,
is associated with an improved quality of life relative to
crizotinib."
The latest results were a 25-month follow up to a Phase III trial.
The study focused on patients with advanced anaplastic lymphoma
kinase-positive (ALK+) non-small cell lung cancer who had not
received a prior ALK inhibitor.
Alunbrig is a tyrosine kinase inhibitor (TKI) designed to target and
inhibit the ALK fusion protein in non-small cell lung cancer. It
received accelerated approval from the U.S. Food and Drug
Administration in April 2017 for certain cancer patients who had
progressed on or were intolerant to crizotinib, a similar class of
drug.
[to top of second column] |
Under the brand name Xalkori, crizotinib delivered $524 million in
sales for Pfizer Inc last year.
Non-small cell lung cancer is the most common form among the
estimated 1.8 million new cases of lung cancer diagnosed each year
worldwide, according to the World Health Organization. The ALK
variant is seen in about 5% of non-small cell cases.
Buying Shire expanded Takeda's drug pipeline and diversified its
global sales, with half of its revenue now coming from the United
States. The company, now the 15th largest drugmaker by revenue, told
investors this week it expects 14 new drugs to deliver about $10
billion in peak yearly sales over the next five fiscal years.
The company hopes to get U.S. regulatory approval for Alunbrig as a
frontline drug for lung cancer in the fiscal year ending March 2021.
Takeda is focusing on five key areas: oncology, gastroenterology,
neuroscience, rare disease and plasma-derived therapies - businesses
that contribute about 75% of its total revenue.
(Reporting by Rocky Swift; Editing by Christopher Cushing)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |